Skip to main content
Fig. 3 | Pediatric Rheumatology

Fig. 3

From: Precision treatment of Singleton Merten syndrome with ruxolitinib: a case report

Fig. 3

Effects of JAK inhibition on body weight and bone mineralization. A Growth chart showing development of height. The grey area indicates is the 5. to 95. percentiles for height of children in Europe. B Growth chart showing development of weight. The grey area indicates is the 5. to 95. percentiles for height of children in Europe. The dark blue vertical line at 9 years indicates start of treatment. C Series of palmar-dorsal hand X-rays of the left hand showing improved mineralization. The time points after initiation of treatment indicated below images. The scale bar on the lower right corner of panel C is 10 mm and applies to all images of panel CD Enlarged images of thumb bones showing resolution of acro-osteolysis

Back to article page